Sequence information
Variant position: 261 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 597 The length of the canonical sequence.
Location on the sequence:
DKVKQGFWEEFETLQQQECK
L LYSRKEGQRQENKNKNRYKN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human DKVKQGFWEEFETLQQQECKL LYSRKEGQRQENKNKNRYKN
Mouse DKVKQGFWEEFETLQQQECKL LYSRKEGQRQENKNKNRYKN
Rat DKVKQGFWEEFETLQQQECKL LYSRKEGQRQENKNKNRYKN
Chicken DKVKQGFWEEFETLQQQECKL LYSRKEGQRQENKNKNRYKN
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 597
Tyrosine-protein phosphatase non-receptor type 11
Domain
247 – 521
Tyrosine-protein phosphatase
Helix
259 – 262
Literature citations
Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.
Pannone L.; Bocchinfuso G.; Flex E.; Rossi C.; Baldassarre G.; Lissewski C.; Pantaleoni F.; Consoli F.; Lepri F.; Magliozzi M.; Anselmi M.; Delle Vigne S.; Sorge G.; Karaer K.; Cuturilo G.; Sartorio A.; Tinschert S.; Accadia M.; Digilio M.C.; Zampino G.; De Luca A.; Cav e H.; Zenker M.; Gelb B.D.; Dallapiccola B.; Stella L.; Ferrero G.B.; Martinelli S.; Tartaglia M.;
Hum. Mutat. 38:451-459(2017)
Cited for: VARIANTS NS1 HIS-261; PHE-261; ARG-262; PHE-262 AND GLN-265; CHARACTERIZATION OF VARIANTS NS1 HIS-261; PHE-261; ARG-262; PHE-262 AND GLN-265; FUNCTION; CATALYTIC ACTIVITY;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.